Literature DB >> 16762637

Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice.

Karin Müller-Decker1, Gerhard Fürstenberger, Nadine Annan, Dagmar Kucher, Andrea Pohl-Arnold, Brigitte Steinbauer, Irene Esposito, Sara Chiblak, Helmut Friess, Peter Schirmacher, Irina Berger.   

Abstract

BACKGROUND & AIMS: Basic research aimed at a better understanding of pancreatic carcinogenesis and improving the treatment of this disease is crucial because the majority of pancreatic cancers are highly aggressive and therapeutically nonaccessible. Cyclooxygenase (COX)-2, which is a key enzyme of prostaglandin (PG) biosynthesis, is overexpressed in around 75% of human carcinomas including those of the pancreas.
METHODS: The pathologic changes of transgenic mouse pancreas with keratin 5-promoter-driven expression and activity of COX-2 were characterized.
RESULTS: Aberrant expression of COX-2 in a few ductal cells and COX-2-mediated PG synthesis in the transgenic mice resulted in keratin 19- and mucin-positive intraductal papillary mucinous neoplasm- and pancreatic intraepithelial neoplasia-like structures, characterized by an increased proliferation index and serous cystadenomas. Moreover, Ras activation was enhanced and the HER-2/Neu receptor was overexpressed. Loss of acini, fibrosis, and inflammation were pronounced. Feeding a COX-2-selective inhibitor to the transgenic mice suppressed the accumulation of PG and the phenotype. The changes resemble the human disease in which COX-2 was overexpressed consistently.
CONCLUSIONS: We present strong evidence for a causal relationship between aberrant COX-2 overexpression and COX-2-mediated PG synthesis and the development of serous cystadenoma, intraductal papillary mucinous, and pancreatic intraepithelial neoplasms. This model offers the unique possibility of identifying molecular pathways leading to the formation and malignant progression of the various types of preinvasive lesions of pancreatic adenocarcinomas that show different dismal outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762637     DOI: 10.1053/j.gastro.2006.03.053

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

Review 1.  Deploying mouse models of pancreatic cancer for chemoprevention studies.

Authors:  Paul J Grippo; David A Tuveson
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-02

2.  Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells.

Authors:  Hiroki Takahashi; Aihua Li; David W Dawson; Oscar Joe Hines; Howard A Reber; Guido Eibl
Journal:  Pancreas       Date:  2011-04       Impact factor: 3.327

3.  Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).

Authors:  Nune Markosyan; Jinyang Li; Yu H Sun; Lee P Richman; Jeffrey H Lin; Fangxue Yan; Liz Quinones; Yogev Sela; Taiji Yamazoe; Naomi Gordon; John W Tobias; Katelyn T Byrne; Andrew J Rech; Garret A FitzGerald; Ben Z Stanger; Robert H Vonderheide
Journal:  J Clin Invest       Date:  2019-06-04       Impact factor: 14.808

4.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.

Authors:  Meredith A Collins; Filip Bednar; Yaqing Zhang; Jean-Christophe Brisset; Stefanie Galbán; Craig J Galbán; Sabita Rakshit; Karen S Flannagan; N Volkan Adsay; Marina Pasca di Magliano
Journal:  J Clin Invest       Date:  2012-01-09       Impact factor: 14.808

5.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

6.  Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.

Authors:  Jennifer Kl Colby; Russell D Klein; Mark J McArthur; Claudio J Conti; Kaoru Kiguchi; Toru Kawamoto; Penny K Riggs; Amy I Pavone; Janet Sawicki; Susan M Fischer
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

7.  Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity.

Authors:  Nina Mayorek; Nili Naftali-Shani; Myriam Grunewald
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

Review 8.  Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer.

Authors:  Craig D Logsdon; Baoan Ji
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11       Impact factor: 11.382

9.  Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.

Authors:  Kotha Subbaramaiah; Robert Benezra; Clifford Hudis; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

10.  Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.

Authors:  Jelena Todoric; Laura Antonucci; Giuseppe Di Caro; Ning Li; Xuefeng Wu; Nikki K Lytle; Debanjan Dhar; Sourav Banerjee; Johan B Fagman; Cecille D Browne; Atsushi Umemura; Mark A Valasek; Hannes Kessler; David Tarin; Michael Goggins; Tannishtha Reya; Maria Diaz-Meco; Jorge Moscat; Michael Karin
Journal:  Cancer Cell       Date:  2017-11-16       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.